Inmune Bio Overview
- Nov 16, 2020 - Psychiatric Times - Blocking Neuroinflammation
- Nov 9, 2020 - WAVE 3 NEWS - Study of COVID treatment Quellor has first patient at Louisville hospital
- Oct 29, 2020 - Nasdaq Trade Talks - Dr. Raymond J. Tesi, MD, CEO & CMO joins @JillMalandrino on @Nasdaq #TradeTalks to discuss what the medical community has learned about treating #COVID19 and the INmuneBio treatment starting Phase 2 human trials
- Oct 28, 2020 - SoundCloud - Harnessing the innate immune system to combat disease, RJ Tesi, CEO and CMO, INmune Bio
- Sep 11, 2020 - Contagion Live - Targeting the Innate Immune System to Neutralize the Cytokine Storm in Severe COVID-19
- Sep 02, 2020 - 10 News San Diego - San Diego biotech takes aim at COVID-19's inflammation and blood clotting with Quellor
- July 14, 2020 - BioCentury - INmune therapy shows promise in Alzheimer’s, but cognitive test still to come
- July 14, 2020 - Investor’s Business Daily - Tiny Biotech Skyrockets To A Record High On Promising Alzheimer's News
- July 14, 2020 - BioWorld - AD not in-‘soluble’ after all? Street likes Inmune’s bet on next-gen TNF
- July 14, 2020 - TD Ameritrade The Watch List - Ceo Of Immune Bio RJ Tesi On The Fight Against Alzheimer's
- June 22-24 - AACR Virtual Annual Meeting II - Soluble TNFα blockade overcomes lapatinib resistance and induces an innate immune response in HER2-positive breast cancer
- April 22 - The San Diego Union Tribune - The small company aims to calm the inflammatory storm that brews in some COVID-19 patients
- April 10 - TD Ameritrade Interview RJ Tesi
- Mar 23, 2020 - Applied Clinical Trials - From Ashes to Flames: Novel Alzheimer’s Disease Pathways Emerge
- Feb 19, 2020 - NextAvenue - Is an Alzheimer’s Vaccine on the Horizon?
- Feb 03, 2020 - Pittwire Health - Immunotherapy Companies Make Strides in Fight Against Cancer
- Jan 16, 2020 - CFO DIVE - CFO touts simplified biopharma cap structure
- Nov 26, 2019 - Technology Networks - New Compound Targets the Link Between Poor Diet, Inflammation and Alzheimer's Disease
- Nov 1, 2019 - 9news - INmune Bio’s XPro1595 May Help Lower Neuroinflammation Triggered by High Fat and Sugar Diet, Mouse Study Suggests
- Sep 27, 2019 - 9news - Australian clinical trials testing new approach to tackling Alzheimer's disease
- Sep 24, 2019 - FiveThirtyEight - How Massachusetts Built A Booming Biotech Ecosystem
- Sep 24, 2019 - BioTuesdays - INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases
- Aug 20, 2019 - Inmuno Oncology News - INmune Bio Shares Early Results of Phase 1 Trial of INB03 for Advanced Cancer Treatment
- July 11, 2019 - Healthline - How Smaller Labs Are Pushing the Research Envelope into Alzheimer's
- July 3, 2019 - Washington Post - "Alzheimer’s research is getting a reboot at small companies focused on the immune system"
- June 25, 2019 - STAT+ - The maddening saga of how Alzheimer's 'cabal' thwarted progress toward a cure for decades
- June 24, 2019 - Seeking Alpha - Pfizer and INmune Bio: Seeking The Blockade of Tumor Necrosis Factor Alpha For Alzheimer's Disease
- June 13, 2019 - Innovation&Tech - Alzheimer’s Research is Gaining Steam with New Clinical Trials
- April 30, 2019 - STAT - After amyloid failures, it's time to take a new tack for treating Alzheimer's
- April 24, 2019 - US News - We Need New Ideas for FIghting Alzheimer's
- April 15, 2019 - US News - Is Alzheimer's Hereditary?
- April 02, 2019 - Inmuno Oncology News - INB03 May Help Reverse Cancer’s Resistance to Immunotherapy, INmune Bio Co-founder Says
- March 05, 2019 - Select Science - This Novel, Non-Amyloid Approach to Alzheimer’s Therapy Could Vastly Improve Outcomes
- March 04, 2019 - Scientific American - For Alzheimer’s Sufferers, Brain Inflammation Ignites a Neuron-Killing “Forest Fire”
- February 22, 2019 - Onco'Zine - Diet and Cancer: What’s the Connection?
- February 20, 2019 - Investing News INmune Bio Pursues Alzheimer’s Treatment in New Clinical Trial
- February 19, 2019 - Everyday Health Does Chronic Inflammation Cause Dementia?
- February 05, 2019 - Genetic Engineering & Biotechnology News Is Cancer Smarter Than We Are?
- February 05, 2019 - Money Inc. Bylines Mediterranean Diet: Sun, Sea, and Olive Oil
- February 01, 2019 - San Diego Business Journal Online From Little Known to IPO: INmune Bio Raises $8.16 Million in Trading Debut
- January 01, 2019 - Money Inc. Bylines Chronic Inflammation: Real Disease, Wrong Name
- January 01, 2019 - Scientific American Are We Innately Immune to Cancer?
- January 01, 2019 - TIPS (Cell Magazine) MDSC: The Most Important Cell You've Never Heard Of
- December, 2018 - Onco'Zine INmune Bio Receives Phase I Clinical Trial Authorization for Lead Product in Ovarian Cancer
- December, 2018 - BioSpace INmune Bio Granted Phase I Clinical Trial Authorization of Lead Product INKmune™ in Refractory and Recurrent Ovarian Cancer Patients
- December, 2018 - TIPS (Cell Magazine) MDSC: The Most Important Cell You've Never Heard Of
- December, 2018 - Money Inc. Bylines Immunotherapy and Checkpoint Inhibitors: Can They Be More Effective?
- November, 2018 - BioProcess International eBook: Partnerships in Immunotherapy
- October 31, 2018 - Diagnostics World News XtalPi, Qure.ai, Thermo Fisher Scientific, And More: News From October 2018
- October 01, 2018 - Select Science Hiding in Plain Sight: How to Break Through the Tumor Microenvironment Forcefield
- September 25, 2018 - Diagnostics World News uBiome, AliveCor, Ariel Precision Medicine, And More: News From September 2018
- September 11, 2018 - Health Professional Radio INmune Bio – Cancer Treatment with Patient’s Own Immune System
- September 01, 2018 - Genetic Engineering & Biotechnology News Cancer Mindset Shifts from Pathology to Immunology
- August 08, 2018 - YourTango: 7 Things That Happen To Your Body After You Turn 30
- August 03, 2018 - Healthcare Global: The shift to tumour-agnostic immunotherapies
- August 01, 2018 - PopSugar: How to Tell If You Have Chronic Inflammation: Experts Explain Why It Can Be So Dangerous
- July 24, 2018 - Clinical Leader: Phase 1 Trial Targets The Immune System, Not The Cancer
- June 04, 2018 - The Hill: Cutting costs could be the key to curing cancer
- May 24, 2018 - R&D Mag Clinical Trial Investigates Novel Innate Immune System Checkpoint Inhibitor for Solid Tumors
- May 24, 2018 - Pharma Journalist INmune Bio Initiates Phase 1 Clinical Trial Of INB03
- April 23, 2018 - STAT: Combination immunotherapy may have failed in the Incyte/Merck trial, but it's here to stay
The Investor Relations website contains information about INMB's business for stockholders, potential investors, and financial analysts. Disclaimer - For Informational Purposes Only - The company assumes no responsibility for the accuracy of reports prepared by outside third parties, nor does it endorse any of the projections, recommendations or conclusions made herein.